Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

Cancer Biology and Therapy

Volumn 9, Issue 8, 2010, Pages 618-631

  Kaplan Lefko, Paula J ^a   Graves, Jonathan D ^b   Zoog, Stephen J ^a   Pan, Yang ^b   Wall, Jason ^b   Branstetter, Daniel G ^b   Moriguchi, Jodi ^a   Coxon, Angela ^a   Huard, Justin N ^b   Xu, Ren ^b   Peach, Matthew L ^b   Juan, Gloria ^a   Kaufman, Stephen ^a   Chen, Qing ^a   Bianchi, Allison ^b   Kordich, Jennifer J ^b   Ma, Mark ^a   Foltz, Ian N ^c   Gliniak, Brian C ^b  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c Amgen British Columbia   (Canada)

Author keywords

Apoptosis; Biomarkers; Caspase; Combination therapy; Conatumumab; Death receptor; TRAIL

Indexed keywords

AMG 655; CASPASE; CASPASE 3; CASPASE 7; CONATUMUMAB; CYTOKERATIN 18; DEATH RECEPTOR 5; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; NEOEPITOPE OF CASPASE CLEAVED CYTOKERATIN 18; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; PANCREAS TUMOR; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 77952912435     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.8.11264     Document Type: Article

References (43)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
2. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75.
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
4. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97.
5. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70.
6. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-6. (Pubitemid 28017080)
7. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7:693-6. (Pubitemid 27408868)
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-8.
9. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10:559-63.
10. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333-9.
11. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611-20.
12. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56.
13. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7:1166-73.
14. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-81.
15. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16:33-45.
16. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481-90.
17. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10.
18. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26:3621-30.
19. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30. (Pubitemid 37328939)
20. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
21. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15:751-61.
22. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166:4891-8.
23. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130:501-10.
24. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280:41940-52.
25. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-60.
26. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005; 11:3126-35.
27. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-41.
28. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003; 8:263-8.
29. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 2008; 19:990-5.
30. Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 2008; 7:455-63.
31. Cummings J, Ranson M, Butt F, Moore D, Dive C. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability cancer patient plasma. Cancer Chemother Pharmacol 2007; 60:921-4.
32. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008; 153:646-56.
33. Babcock J, Leslie K, Olsen O, Salmon R, Schrader A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA 1996; 93:7843-8.
34. Lippa MS, Strockbine LD, Tiep TL, Branstetter DG, Strathdee CA, Holland PM. Expression of anti-poptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 2007; 12:1465-78.
35. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5.
36. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13:1070-7.
37. Amgen data on file.
38. Sanger Institute. Cancer Cell Line Project 2009; [cited 2009]; Available from: http://www.sanger.ac.uk/genetics/CGP/CellLines/.
39. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007; 67:9364-70.
40. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol 2006; 24:3047.
41. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007; 13:3198-206.
42. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006; 94:1592-8.
43. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56:399-404.